-
Alemtuzumab Induction as a Mediator of Nonadherence in Renal Transplantation
-
Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients
-
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
-
All DQ DSA May Not Be Equal: Comparing Outcomes between De Novo DQ DSA Specificities
-
Allogeneic Mesenchymal Stem Cells as Induction Therapy Are Safe and Feasible in Renal Allografts: Pilot Results of a Multicenter Randomized Controlled Trial
-
Allogeneic T Follicular and T Conventional Responses Assessed by Proliferation, Cytokine Production, and TCR Clonality
-
Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study
-
Alloreactive B Cells Acquire Cell-Intrinsic Hyporesponsiveness in Tolerant Recipients
-
Altered Function of Cytomegalovirus Specific T Cells in Transplant Recipients
-
Alveolar Macrophages Derived from MCMV Latently Infected Donors Drives the Viral Reactivation and Dissemination Following the Orthotopic Left Lung Transplantation in Mice
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 211
- Next Page »